Supplementary Table S1. Response to biological treatment of patients in Table 1

	Mepolizumab	**Omalizumab**
Blood eosinophils (cells/μl)		
Pre-treatment	598.6 ± 694.6	278.0 ± 188.6
On treatment	65.7 ± 31.0 (**p=0.02**)	200.0 ± 185.1 (p=0.43)
FeNO (ppb)		
Pre-treatment	52.8 ± 28.8	35.6 ± 36.6
On treatment	49.1 ± 35.0 (p=0.60)	22.9 ± 12.1 (p=0.47)
FEV1 (% predicted)		
Pre-treatment	77.8 ± 17.8	69.0 ±23.2
On treatment	71.3 ± 13.3 (p=0.087)	69.0 ± 22.2 (p=1)
FEV1 postBD (% predicted)		
Pre-treatment	81.9 ± 19.2)	74.4 ± 22.7
On treatment	80.8 ± 13.5 (p=0.78)	79.5 ± 20.2 (p=0.45)
Exacerbations/year		
Pre-treatment	2.60 ± 1.51	2.22 ± 1.79
On treatment	0.13 ± 0.28 (**p=7.1x10^{-4}**)	0.38 ± 0.55 (**p=0.015**)
ACQ		
Pre-treatment	2.50 ± 1.76	3.41 ±0.89
On treatment	1.57 ± 0.68 (p=0.21)	2.91 ±1.22 (p=0.24)

Results are expressed as mean ± SD and p-values are given for comparisons of variables pre- and post-establishment of the treatment in each patients group (paired t-tests). ACQ: asthma control questionnaire; FeNO: exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; postBD: post-bronchodilator treatment.